David A. Siegel Mersana Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 937,000 shares of MRSN stock, worth $9.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

937,000

Previous 258,200 262.9%

Holding current value

$9.49 Million

Previous $87,000 222.99%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.26 - $0.41 $176,488 - $278,308	678,800 Added 262.9%	937,000 $281,000
Q1 2025 May 15, 2025	SELL	$0.34 - $1.4 $64,532 - $265,720	-189,800 Reduced 42.37%	258,200 $87,000
Q4 2024 Feb 14, 2025	SELL	$1.42 - $2.68 $55,096 - $103,984	-38,800 Reduced 7.97%	448,000 $640,000
Q3 2024 Nov 14, 2024	SELL	$1.23 - $2.25 $285,975 - $523,125	-232,500 Reduced 32.32%	486,800 $920,000
Q2 2024 Aug 14, 2024	BUY	$2.0 - $4.45 $1.13 Million - $2.51 Million	563,500 Added 361.68%	719,300 $1.45 Million
Q1 2024 May 15, 2024	BUY	$2.16 - $5.94 $9,504 - $26,136	4,400 Added 2.91%	155,800 $697,000
Q4 2023 Feb 14, 2024	SELL	$1.11 - $2.34 $232,323 - $489,761	-209,300 Reduced 58.03%	151,400 $351,000
Q3 2023 Nov 14, 2023	SELL	$1.06 - $3.91 $230,444 - $850,034	-217,400 Reduced 37.61%	360,700 $458,000
Q2 2023 Aug 14, 2023	SELL	$3.08 - $9.55 $697,312 - $2.16 Million	-226,400 Reduced 28.14%	578,100 $1.9 Million
Q1 2023 May 15, 2023	SELL	$4.0 - $7.02 $995,200 - $1.75 Million	-248,800 Reduced 23.62%	804,500 $3.31 Million
Q4 2022 Feb 14, 2023	SELL	$5.65 - $7.86 $363,860 - $506,184	-64,400 Reduced 5.76%	1,053,300 $6.17 Million
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $143,530 - $248,000	31,000 Added 2.85%	1,117,700 $7.56 Million
Q2 2022 Aug 15, 2022	SELL	$2.84 - $5.0 $746,352 - $1.31 Million	-262,800 Reduced 19.47%	1,086,700 $5.02 Million
Q1 2022 May 16, 2022	BUY	$3.74 - $6.63 $1.12 Million - $1.98 Million	299,300 Added 28.5%	1,349,500 $5.39 Million
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $2.3 Million - $4.14 Million	420,200 Added 66.7%	1,050,200 $6.53 Million
Q3 2021 Nov 15, 2021	BUY	$8.56 - $14.47 $534,144 - $902,928	62,400 Added 10.99%	630,000 $5.94 Million
Q2 2021 Aug 16, 2021	SELL	$13.28 - $18.07 $253,648 - $345,137	-19,100 Reduced 3.26%	567,600 $7.71 Million
Q1 2021 May 17, 2021	BUY	$15.31 - $26.52 $1.48 Million - $2.57 Million	96,800 Added 19.76%	586,700 $9.49 Million
Q4 2020 Feb 16, 2021	BUY	$16.84 - $27.59 $3.29 Million - $5.39 Million	195,400 Added 66.35%	489,900 $13 Million
Q3 2020 Nov 16, 2020	BUY	$16.2 - $25.7 $2.8 Million - $4.44 Million	172,900 Added 142.19%	294,500 $5.48 Million
Q2 2020 Aug 14, 2020	BUY	$5.24 - $23.4 $367,324 - $1.64 Million	70,100 Added 136.12%	121,600 $2.85 Million
Q1 2020 May 15, 2020	BUY	$4.41 - $9.28 $62,181 - $130,847	14,100 Added 37.7%	51,500 $300,000
Q4 2019 Feb 14, 2020	BUY	$1.45 - $6.73 $2,175 - $10,095	1,500 Added 4.18%	37,400 $214,000
Q3 2019 Nov 14, 2019	BUY	$1.54 - $4.2 $37,576 - $102,480	24,400 Added 212.17%	35,900 $57,000
Q2 2019 Aug 14, 2019	BUY	$3.84 - $6.4 $44,160 - $73,600	11,500 New	11,500 $47,000

Others Institutions Holding MRSN

# of Institutions

Shares Held

94.1M

Call Options Held

34.3K

Put Options Held

14K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $984M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account